Instanyl intranasal fentanyl spray: Phase III data

Data from 86 evaluable patients in the open-label, crossover Phase III FT-019-IM trial showed that Instanyl resulted in meaningful pain relief (greater than or equal to 33% reduction in PI score) in more episodes than Actiq transmucosal fentanyl at 5 minutes (25% vs. 6.8%, p<0.001) and at 10 minutes (51% vs. 23.6%, p<0.001). Both treatments were well tolerated. Data were presented at the European Federation of Chapters of the International Association for the Study of Pain meeting. ...